In PD mouse models, intranasal administration of FGF21-overexpressing MSCs before or after PD induction effectively alleviated motor symptoms, reduced dopaminergic neuronal death, and restored brain-derived neurotrophic factor (BDNF) levels in the SN. This evidence concerns the gene FGF21 and Parkinson disease.